Compare VanEck Gold Miners ETF (GDX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Novo Nordisk A/S — how do they compare? VanEck Gold Miners ETF trades at $89.29 (market cap $25.65B), while Novo Nordisk A/S trades at $38.48 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6.4× VanEck Gold Miners ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Novo Nordisk A/S for 116 Days on average.
| GDX | NVO | |
|---|---|---|
Market Cap | $25.65B | $165.31B |
Volume | 16,534,046 | 11,432,838 |
52-Week High | $115.84 | $63.98 |
52-Week Low | $68.28 | $35.29 |
Typical Hold Time | 76 Days | 116 Days |
Sector | — | Health |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.24, up 4.42% today but facing bearish technical signals with 15 sell indicators versus 4 buy signals. The ETF remains 22% below its peak despite gold trading near $4,270, creating a potential catch-up opportunity. Recent institutional activity shows mixed sentiment with Allworth Financial and HB Wealth Management reducing positions while Ameritas Advisory Services increased its stake by 315.7%.
Gold miners offer leverage to gold prices but face volatility from interest rate sensitivity and operational risks. Current technical weakness suggests near-term pressure, though long-term fundamentals remain supported by gold's defensive characteristics amid macroeconomic uncertainty. The divergence between physical gold performance and miner valuations presents both risk and opportunity for investors.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
